Systematic review shows empagliflozin improves quality of life and reduces costs in chronic kidney disease patients, indicating its value across healthcare systems.
Objective: To evaluate the cost-effectiveness of empagliflozin in patients with chronic heart failure with preserved ejection fraction (CHFpEF) and moderately reduced ejection fraction (CHFmEF) across different healthcare systems. Materials and Methods: A systematic review was conducted following the PRISMA (2024) methodology. Studies were identified through searches in PubMed, Web of Science, ScienceDirect, and Google Scholar using the keywords: empagliflozin, chronic heart failure, cost-effectiveness, QALY, ICER. Studies assessing patients' costs, quality of life, and life expectancy were included. Results: The analysis demonstrated that empagliflozin reduces hospitalization rates for heart failure, increases life expectancy, and improves quality of life (QALY). The drug's cost-effectiveness varies by region: Australia—ICER = 29,202 AUD/QALY; USA—ranging from 437,442 USD/QALY to 87,725 USD/QALY; Spain—5,089 EUR/QALY; China—11,292 USD/QALY. Conclusions: The addition of empagliflozin to standard therapy is cost-effective in most cases, particularly in countries with high hospitalization costs. Further research is needed to assess its long-term effects.
No takes yet. Share an insight, caveat, or question.
Nargiza et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: